Overview

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Status:
Active, not recruiting

Trial end date:
2022-12-29

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of UTTR1147A compared with vedolizumab and with placebo in the treatment of participants with moderate to severe UC. This study will consist of two parts, Part A and Part B. Part A will test the induction of clinical remission and Part B will test the durability of clinical remission.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Vedolizumab